CRYOPORT, INC. Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment
CRYOPORT, INC. (CYRX) reported Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment of -$50.00 thousand for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-05.
Discontinued › Income Statement › Other Income
us-gaap:DebtAndEquitySecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairment · last filed 2022-05-05
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2022-03-31 was -$50.00K.
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2021-09-30 was -$10.00K.
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for the quarter ending 2021-06-30 was $80.00K, a 1532.65% increase year-over-year.
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for fiscal 2021 was $80.00K, a 166.67% increase from fiscal 2020.
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for fiscal 2020 was $30.00K, a 62.50% decline from fiscal 2019.
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for fiscal 2019 was $80.00K.
- CRYOPORT, INC. debt and equity securities, realized gain (loss), excluding other-than-temporary impairment for fiscal 2018 was $0.00.
| Period end | Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment 3 month | Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment 3 month as first filed | Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment 6 month | Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment 9 month | Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment 12 month | Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-03-31 | -$50.00K 10-Q · filed 2022-05-05 | -$50.00K derived: sum of 2 quarters · filed 2022-05-05 | -$60.00K derived: sum of 3 quarters · filed 2022-05-05 | $20.00K derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$10.00K derived: sum of 2 quarters · filed 2022-02-28 | $70.00K derived: sum of 3 quarters · filed 2022-02-28 | $80.00K 10-K · filed 2022-02-28 | ||
| 2021-09-30 | -$10.00K 10-Q · filed 2021-11-04 | $70.00K derived: sum of 2 quarters · filed 2021-11-04 | $80.00K 10-Q · filed 2021-11-04 | $50.00K derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-06-30 | $80.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $40.00K 10-Q · filed 2021-08-06 | $60.00K derived: sum of 3 quarters · filed 2022-05-05 | $53.10K derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2021-03-31 | -$40.00K 10-Q · filed 2022-05-05 | $40.00K 10-Q · filed 2021-05-06 | -$20.00K derived: sum of 2 quarters · filed 2022-05-05 | -$26.90K derived: sum of 3 quarters · filed 2022-05-05 | -$22.00K derived: sum of 4 quarters · filed 2022-05-05 | |
| 2020-12-31 | $20.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $13.10K derived: sum of 2 quarters · filed 2022-02-28 | $18.00K derived: sum of 3 quarters · filed 2022-02-28 | $30.00K 10-K · filed 2022-02-28 | $32.40K 10-K · filed 2021-03-01 | |
| 2020-09-30 | -$6.90K 10-Q · filed 2020-11-06 | -$2.00K derived: sum of 2 quarters · filed 2020-11-06 | $10.00K 10-Q · filed 2020-11-06 | $26.43K derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $4.90K 10-Q · filed 2020-08-10 | $16.90K 10-Q · filed 2020-08-10 | $33.33K derived: sum of 3 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $10.93K 10-Q · filed 2020-05-08 | $28.43K derived: sum of 2 quarters · filed 2022-02-28 | ||||
| 2019-12-31 | $17.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $80.00K 10-K · filed 2022-02-28 | $81.70K 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $62.50K 10-Q · filed 2019-11-12 | |||||
| 2018-12-31 | $0.00 10-K · filed 2020-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |